Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash from Operations (2016 - 2025)

Guided Therapeutics' Cash from Operations history spans 10 years, with the latest figure at 277000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 41.44% year-over-year to 277000.0; the TTM value through Sep 2025 reached 1109000.0, up 1.25%, while the annual FY2024 figure was 1119000.0, 35.91% up from the prior year.
  • Cash from Operations for Q3 2025 was 277000.0 at Guided Therapeutics, down from 169000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 159000.0 in Q4 2021 and bottomed at 739000.0 in Q3 2021.
  • The 5-year median for Cash from Operations is 336000.0 (2023), against an average of 353315.79.
  • The largest annual shift saw Cash from Operations soared 148.04% in 2021 before it tumbled 313.21% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 159000.0 in 2021, then tumbled by 313.21% to 339000.0 in 2022, then rose by 0.88% to 336000.0 in 2023, then grew by 1.19% to 332000.0 in 2024, then rose by 16.57% to 277000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Cash from Operations are 277000.0 (Q3 2025), 169000.0 (Q2 2025), and 331000.0 (Q1 2025).